Absorption Pharmaceuticals to Attend Urological Conference with Its Ground Breaking Treatment for Premature Ejaculation

Absorption Pharmaceuticals , makers of Promescent, a cutting edge treatment for premature ejaculation (PE), will participate in the Urology Association of Physician Assistants Conference (UAPA) in Las Vegas, NV January 20-22. Anthony Balchunas, President-Elect for UAPA, says "I am very excited about Absorption Pharmaceuticals being an active participant in our upcoming annual CME meeting in Las Vegas. The meeting promises to bring state-of-art lectures on a variety of Urological topics including several sessions focusing on sexual health issues. How fitting for Absorption, with their revolutionary product for the treatment of premature ejaculation (Promescent), to be a part of this inaugural meeting."According to Absorption Pharmaceutical CEO Jeff Abraham, one of the primary objectives at Absorption Pharmaceuticals is to educate physicians and clinicians about the physical and mental effects of premature ejaculation. PE affects 30% of the male population. Due to the lack of treatment options, PE is often confused or treated with erectile dysfunction medication. Often these patients suffer from both of these conditions and require dual therapy: pharmacological and behavioral.“Since our inception, we have worked closely with industry experts to insure the integrity of our educational and marketing efforts", says Abraham. "We are firmly committed to continuing the focus of utilizing our resources to strengthen our expanding presence in the areas of both Urology and sexual medicine."In 2011, Absorption Pharmaceutical participated in conferences sponsored by the America Urology Association (AUA) in Chicago, International Society for Men’s Health (ISMH) in Vienna Austria, Sexual Medicine Society of North America (SMSNA) in Las Vegas, and the European Sexual Society of Medicine (ESSM) in Milano, Italy. In addition to the upcoming UAPA meeting in January, Absorption Pharmaceuticals will also be sponsoring an educational lecture at the Association of Sexual Educators, Clinicians, and Therapists (ASECT) conference in June in Austin. AP has also planned to participate in the SMSNA/ISSM conference in August in Chicago.Mr. Balchunas adds, “One of our goals for the upcoming UAPA meeting is to bring valuable, up-to-date information and education to the participants in attendance. Products like Promescent positively impact the way we treat our patients and educate them about the common problem of PE. We appreciate Absorption's role in the support of the education process. The end result is better patient care as more clinicians become aware of Promescent's efficiency, safety, cost-effectiveness, and ease of use."